



Clinical Guidance

Paediatric Critical Care: Severe Asthma

Summary

This guidance offers advice for staff treating children with severe asthma. It offers advice on treatment, ventilation techniques and patient assessment. It also refers to treatment within a PICU setting. Advice on salbutamol dosing differs between British Thoracic Society guidelines and the BNF. STRS has chosen the lower dosing due to concerns of salbutamol toxicity. There is also evidence that patients requiring critical care are more likely to have mucus plugs rather than bronchospasm.

Document Detail				
Document type	Clinical Guideline			
Document name	Paediatric Critical Care: Severe Asthma			
Document location	Evelina London website			
Version	v3			
Effective from	14 th July 2021			
Review date	14 th July 2024			
Owner	PICU Head of Service			
Author(s)	Andrew Nyman, Jon Lillie (PICU Consultants)			
Approved by, date	Evelina London Clinical Guidelines Committee, July 2021			
Superseded documents	v2			
Related documents	British Thoracic Society 2019 guidance on asthma			
Keywords	Evelina, child, Paediatric, intensive care, STRS, Retrieval, Paediatric critical care, asthma, wheeze, PICU.			
Relevant external law, regulation, standards				
This clinical guideline has been produced by the South Thames Retrieval Service (STRS) at Evelina London for nurses, doctors and ambulance staff to refer to in the emergency care of				

critically ill children. This guideline represents the views of STRS and was produced after careful consideration of available evidence in conjunction with clinical expertise and experience. The guidance does

not override the individual responsibility of healthcare professionals to make decisions

appropriate to the circumstances of the individual patient.

Glossary: MgSO4 is magnesium sulphate, DNAse= Dornase Alfa

Change History				
Date	Change details, since approval	Approved by		
July 21	Avoid nebs with salbutamol infusion as toxicity	ELCGC		
	Advice for post extubation care and follow up clarified			

Severe Asthma

Asthma is reversible airflow obstruction (β 2 bronchodilator responsive).

Lack of reversibility/paradoxical deterioration with treatment: a) mucus plugs b) rarely other pathology (tracheomalacia, vascular rings,

foreign body, congestive cardiac failure and compressive airway masses). **Risk factors for fatal asthma:** (usually pre-hospital event) brittle asthma, heavy use β2 bronchodilators, previous ICU admission

Risk factors for fatal asthma: (usually pre-hospital event) brittle asthma, heavy use β2 bronchodilators, previous ICU admission					
Standard treatment for acute asthma (as per BTS guideline)		CXR to look for:			
FIRST LINE	 Oxygen to maintain saturation >94% Salbutamol MDI 2-10 puffs (can be repeated) Nebulised Salbutamol 2.5 -5mg MAX every 20-30 minutes Ipratropium bromide 250 micrograms nebulized, then 4 to 6 hourly Oral prednisone 20mg if <5yr, 40mg if >5yr 2mg/kg if on maintenance steroids, MAX 60mg (3 days usually enough) 4mg/kg IVI hydrocortisone (Max 100mg) if oral not tolerated 	 Atelectasis / consolidation Pneumothorax Alternative diagnosis (airway compression, foreign body) Gases Arterial/venous blood gas can be useful to monitor: lactate (salbutamol toxicity), K+, CO₂ if concerns of fatigue 			
		Do not use cap gas-(CO ₂ error high)			
SECOND LINE	 • 40 mg/kg IVI MgSO₄ over 30min (Max 2 grams) (may help mucus plug lysis) (Consider 2nd dose if positive response. Side effect hypotension - monitor BP) • IVI Salbutamol infusion (0.5 to 1mcg/kg/min – MAX 20micrograms/min) Monitor for hypokalemia. Side effect = tachycardia, lactic acidosis Risk of increasing > 1mcg/kg/min OR additional nebs as side effects ↑ (agitation, tachycardia, hypokalaemia, lactic acidosis-worsens resp function) 	 Asthma severity can be difficult to assess Tachycardia universal with β₂ stimulants Respiratory rate varies with respiratory drive vs fatigue (slow breathing suggests fatigue) Agitation or drowsiness may occur Concerned or lack of response to therapy seek consultant paediatric & anaesthetic review 			
	 If Aminophylline DGH policy:5 mg/kg over 20 min then 0.5-1mg/kg/h (Max dose: 0.8mg/kg/h if 9-15 yrs, ≥16 yrs 0.5mg/kg/h). Monitor levels as narrow therapeutic range and side effects common 	 Reduce IV salbutamol < 0.5 mcg/kg/min as can cause lactic acidosis (↑ glycolysis) NO nebs if ventilated or on IV salbutamol Farly physictherapy apiping 			
 Consider intubation if failure to respond to above therapy: Saturation< 92% despite high flow nasal cannula/facemask O₂ Hypercarbia CO₂ > 6kpa (rare in acute asthma = sign of fatigue), Inability to speak short sentences (severe airflow obstruction) Poor air entry/absent wheeze Intubation is high risk (may be difficult to ventilate – use cuffed ETT) Pre oxygenate adequately (3 min). Rarely CO₂ may rise with O₂. Ketamine (2mg/kg IV) / Rocuronium 1mg/kg as muscle relaxation. BP may fall if dynamic hyperinflation / air trapping: may need IV fluid boluses Use end tidal (if dead space high, end tidal 50-60% of true CO₂) if end tidal does not reach plateau = incomplete expiration Post intubation CXR mandatory Don't manually decompress chest (risk cardiac arrest if air trapping is dynamic) 		 Bronchoscopy if diagnosis uncertain or poor response to treatment As patient improves use pressure support 10-30cm H₂0 (not SIMV).Titrate to WOB. Refer to tertiary respiratory team who must review prior to discharge or transfer to referring hospital Review asthma therapy after extubation and consider length of steroids Allergy review if history suggests anaphylaxis Criteria for endotracheal dornase alfa PIP > 28 cm H₂0 Insp peak to plateau pressure > 10 cm H₂0 Not ventilated but > 48hrs of IV salbutamol & no clinical improvement In severe cases bronchoscopy with PICU consultant 			
 U H If F S H E If M E a If c P le 	The vertication principles (saturations > 90% are adequate) as pressure control mode with muscle relaxation (SIMV may autotrigger). Severe, PIP 40-50 cm H ₂ 0 may be needed if inspiratory peak to plateau >10 ixed PEEP at 5 cm H ₂ 0 (do not routinely measure auto-PEEP to adjust) LOW RATE 10 - 15 bpm (flow should reach zero before next breath) ligh CO ₂ is acceptable (7-14kPa) provided control achieved and improving nd tidal CO ₂ often does not correlate with arterial CO ₂ (deadspace ventilation) n ICU setting use tidal volume and flow loops (see figures) leasure inspiratory peak to plateau difference to estimate large airway resistance nsure adequate minute ventilation (tidal volumes may need to be 8-10ml/kg min nd inspiratory breath should start as soon as expiration finishes) ventilation difficult, use manual bagging with enough pressure to move the hest. Allow enough time for expiration (plateau on ETCO ₂) ERSISTING HYPERCARBIA – Troubleshoot cause (Tube obstruction or eak, pneumothorax, mucous plugs)	 Response to dornase alfa may be dramatic: reduce PIP as tidal volumes increase Flow time loops ensuring complete expiration Inspiratory hold to measure peak to plateau peak End insp pause pressure drop 			
Investigations and follow up arrangements Chest Xray review 					

- Full blood count inc. eosinophil/WBC differential
- Serum IgE (and specific IgE house dust mite, aspergillus, moulds mix, cat & dog).
- Serum tryptase (within 1st 24hrs admission to hospital)
- Bronchoalveolar lavage (if ventilated) Cytology (differential count incl. fat laden macrophages), Culture (bacterial, fungal & AFB's)
- Respiratory viral panel (incl. HSV and CMV)
- Inpatient paediatric asthma team review prior to discharge or transfer to referral hospital
- GP/local paediatrician review in 48hrs
- Respiratory (asthma consultant) clinic in 2-4 weeks & severe and difficult asthma service follow up in 3 months

References: 1) www.brit-thoracic.org.uk 2) Stather, Crit Care, 2005 3) Durward, CritCare Med 2000 4) Tobin, Crit Care Resus 2005

ELCGC Ref: 21065

